高级检索
当前位置: 首页 > 详情页

Minimally invasive surgery could be attempted with preoperatively predictable difficulty for non-small cell lung cancer after neoadjuvant immunochemotherapy: A large multicenter study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Sch Med,Dept Thorac Surg Oncol, 241 Huaihai West Rd, Shanghai 200030, Peoples R China [2]Ningbo Univ, Lihuili Hosp, Dept Cardiothorac Surg, Ningbo, Peoples R China [3]Ningbo Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Ningbo, Peoples R China [4]Zhoushan Putuo Dist Peoples Hosp, Dept Thorac Surg, Zhoushan, Peoples R China [5]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Dept Thorac Surg, Sch Med, Shanghai, Peoples R China [6]First Peoples Hosp Fuyang Hangzhou, Dept Emergency & Crit Care Med, Hangzhou, Peoples R China [7]Zhejiang Univ, Shaoxing Shengzhou Peoples Hosp, Affiliated Hosp 1, Shengzhou Branch, Shaoxing, Peoples R China [8]Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Shanghai, Peoples R China [9]Wenzhou Peoples Hosp, Dept Clin Med, Wenzhou, Peoples R China [10]Wenzhou Cent Hosp, Fac Clin Res & Med, Wenzhou, Peoples R China [11]Wenzhou Ruian Peoples Hosp, Dept Respirat & Crit Care Med, Wenzhou, Peoples R China [12]Shaoyang Univ, Dept Thorac Surg, Affiliated Hosp 1, Shaoyang, Peoples R China [13]Cent Hosp Shaoyang, Dept Thorac Surg, Shaoyang, Peoples R China [14]Jingdezhen Second Peoples Hosp, Dept Cardiothorac Surg, Jingdezhen, Peoples R China [15]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Res Inst, Sch Med, Dept Thorac Surg, Chengdu, Peoples R China [16]Ningbo Beilun Peoples Hosp, Dept Cardiothorac Surg, Ningbo, Peoples R China [17]Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai Lung Canc Ctr,Dept Oncol, Shanghai, Peoples R China
出处:
ISSN:

摘要:
Background: Neoadjuvant immunochemotherapy has revolutionized the treatment of non-small cell lung cancer. However, it presents significant surgical challenges, leading to controversy over the feasibility and safety of minimally invasive surgery. This study aims to assess the adequacy of minimally invasive surgery and preoperatively predict its difficulty for non-small cell lung cancer after neoadjuvant immunochemotherapy. Methods: Initial stage IIA-IIIB (excluding stage T4N2) non-small cell lung cancer patients with neoadjuvant immunochemotherapy undergoing minimally invasive surgery or open thoracotomy at 12 institutions between 2019 and 2024 were retrospectively reviewed. Difficult minimally invasive surgery was defined by conversion to thoracotomy. Propensity score matching was applied to balance baseline characteristics. Results: Of the 571 cases included, propensity score matching led to 240 patients per group. Minimally invasive surgery decreased intraoperative bleeding, shortened postoperative chest tube duration and hospitalization, ameliorated postoperative pain, and reduced postoperative complications compared to open thoracotomy. Moreover, minimally invasive surgery had an acceptable conversion rate of 15.8%, and notably, converted minimally invasive surgery achieved similar perioperative outcomes to open thora-cotomy. Accumulated surgeons' experiences reduced minimally invasive surgery conversion rates and shortened surgical durations. Additionally, logistic regression identified squamous cell carcinoma, advanced preinduction N stage, preoperative tumor size >5 cm, advanced preoperative stage, and extended resection as independent risk factors for conversion. A nomogram was further established with good performance (area under curve value 1/4 0.804) and clinical utility to predict conversion probability preoperatively. Finally, minimally invasive surgery and open thoracotomy achieved comparable event-free survival and overall survival profiles. Conclusions: Minimally invasive surgery achieved improved perioperative outcomes and similar onco-logic efficacies to open thoracotomy. Moreover, minimally invasive surgery had an acceptable conversion rate, which would not compromise perioperative outcomes compared with open thoracotomy and could be effectively forecasted by a prediction model. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 外科
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 外科
JCR分区:
出版当年[2023]版:
Q1 SURGERY
最新[2024]版:
Q1 SURGERY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Sch Med,Dept Thorac Surg Oncol, 241 Huaihai West Rd, Shanghai 200030, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28508 今日访问量:0 总访问量:1584 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)